Savara Inc. (NASDAQ:SVRA) is one of the best stocks under $5 with highest upside potential. On October 23, Citizens JMP lifted its price target on Savara Inc. (NASDAQ:SVRA) to $11 from $8 while keeping an Outperform rating on the shares. The firm told investors in a research note that its pulmonologist survey shows solid demand for Molbreevi, with 60% of those surveyed expressing an inclination to use it. This, according to Citizens JMP, should mean blockbuster sales, with Savara Inc. (NASDAQ:SVRA) set t ...

Savara Inc. (NASDAQ:SVRA) is one of the best healthcare penny stocks to buy now. On September 9, Guggenheim raised its price target of the stock to $11 from $8 while reiterating a Buy rating. The price target hike follows an impressive 16% stock rally year to date. Guggenheim Lifts Savara (SVRA) Price Target on Pulmonary Alveolar Proteinosis Opportunity The research firm raised its price target, buoyed by positive developments that affirm long-term prospects. For starters, the company has achieved alignm ...